CKD Bio Corp
KRX:063160
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| KR |
|
CKD Bio Corp
KRX:063160
|
117.1B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1.1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
564.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
287.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.9B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
229.6B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.2B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
98.9B EUR |
Loading...
|
Market Distribution
| Min | -168 471.3% |
| 30th Percentile | -2.9% |
| Median | 1.9% |
| 70th Percentile | 5.8% |
| Max | 21 012.5% |
Other Profitability Ratios
CKD Bio Corp
Glance View
CKD Bio Corp. engages in the development and manufacture of active pharmaceutical ingredients. The company is headquartered in Seoul, Seoul. The company went IPO on 2001-12-11. The firm mainly provides antibiotic ingredients, consisting of demethylchlortetracyclines (DMCTs) and rifampicins. The company also provides immunosuppressive agents, including cyclosporin and tacrolimus; remedies for diabetes, such as acarbose, and potassium clavulanate used for beta-lactam inhibitors. The firm distributes its products within domestic market and to overseas markets, such as America, China, Europe, Africa, Southeast Asia, Latin America and the Middle East.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for CKD Bio Corp is -0.4%, which is above its 3-year median of -5.5%.
Over the last 3 years, CKD Bio Corp’s Net Margin has increased from -6.8% to -0.4%. During this period, it reached a low of -15.1% on Dec 31, 2023 and a high of 5.1% on Dec 31, 2024.
